IP Library Granted Patent US 8,598,124
Granted Patent B2
US 8,598,124 · App. 13/141,358 · Granted Dec 3, 2013

Peptides derived from HMG-CoA reductase and cosmetic and/or pharmaceutical composition containing same

Inventors: Claude Dal Farra (Kerhonkson, NY); Nouha Domloge (Valbonne, FR); Jean-Marie Botto (Valbonne, FR)
Assignee: ISP Investments Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,598,124
App. No.
13/141,358
Granted
Dec 3, 2013
Kind
B2
Abstract

The present invention relates to peptides derived from human HMG-CoA reductase of general formula (I): R 1 -(AA) n -X1-Gly-Lys-X2-(AA) p -R 2 , And of sequence SEQ ID No. 1 to SEQ ID No. 10. The present invention also relates to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I), in a physiologically suitable medium. The present invention further relates to the use of this novel peptide as an active principle that activates human HMG-CoA reductase in a cosmetic composition intended to strengthen the barrier function of the skin and to stimulate epidermal differentiation. The invention further applies to a cosmetic treatment method intended to prevent and/or combat the external stresses and signs of cutaneous aging.

Claims (81)

1. A peptide derived from human HMG-CoA reductase, wherein the peptide is one of the following sequences:

(SEQ ID NO: 1)

Glu-Gly-Lys-Gly-Lys-Ser-Val-Val-Cys-Glu,

(SEQ ID NO: 2)

Glu-Gly-Lys-Gly-Lys-Ser-Val-Val,

(SEQ ID NO: 3)

Asp-Gly-Lys-Gly-Lys-Thr,

(SEQ ID NO: 4)

Arg-Gly-Lys-Ser,

(SEQ ID NO: 5)

Arg-Gly-Lys-Ser-NH 2 ,

(SEQ ID NO: 6)

Arg-Gly-Lys-Thr,

(SEQ ID NO: 7)

Arg-Gly-Lys-Thr-NH 2 ,

(SEQ ID NO: 8)

Lys-Gly-Lys-Ser,

(SEQ ID NO: 9)

Lys-Gly-Lys-Ser-NH 2,  and

(SEQ ID NO: 10)

Gly-Lys-Ser-NH 2 .

2. The peptide according to claim 1 wherein the peptide corresponds to the SEQ ID NO: 4 sequence.

3. The peptide according to claim 1 wherein the peptide corresponds to the SEQ ID NO: 5 sequence.

4. The peptide according to claim 1 , wherein the peptide is solubilized in one or more physiologically acceptable solvents selected from the group consisting of water, glycerol, ethanol, propylene glycol, butylene glycol, dipropylene glycol, ethoxylated diethylene glycol or propoxylated diethylene glycol, cyclic polyols, white petroleum jelly, vegetable oil and combinations thereof.

5. A cosmetic composition comprising at least one peptide derived from human HMG-CoA reductase, wherein the peptide is one of the following sequences:

(SEQ ID NO: 1)

Glu-Gly-Lys-Gly-Lys-Ser-Val-Val-Cys-Glu,

(SEQ ID NO: 2)

Glu-Gly-Lys-Gly-Lys-Ser-Val-Val,

(SEQ ID NO: 3)

Asp-Gly-Lys-Gly-Lys-Thr,

(SEQ ID NO: 4)

Arg-Gly-Lys-Ser,

(SEQ ID NO: 5)

Arg-Gly-Lys-Ser-NH 2 ,

(SEQ ID NO: 6)

Arg-Gly-Lys-Thr,

(SEQ ID NO: 7)

Arg-Gly-Lys-Thr-NH 2 ,

(SEQ ID NO: 8)

Lys-Gly-Lys-Ser,

(SEQ ID NO: 9)

Lys-Gly-Lys-Ser-NH 2 ,

(SEQ ID NO: 10)

Gly-Lys-Ser-NH 2 ; and

a physiologically acceptable medium;

wherein the peptide is present in the medium, as an active agent, alone or in combination with at least one other active principle agent.

6. The cosmetic composition according to claim 5 , wherein said peptide is present at a concentration of between 0.0005 and 500 ppm.

7. The cosmetic composition according to claim 6 , wherein said peptide is present at a concentration of between 0.01 and 5 ppm.

8. The cosmetic composition according to claim 5 wherein the composition is a topically administrable composition in the form of a cream, an oil in water emulsion, a water in oil emulsion, a solution, a suspension, a gel, a milk, a lotion, a stick, or a powder.

9. The cosmetic composition according to claim 5 , comprising an effective quantity of the peptide as an active agent that activates human HMG-CoA reductase.

10. A method for cosmetic treatment of skin, the method comprising:

topically applying, to skin to be treated, a composition comprising an effective quantity of a peptide derived from human HMG-CoA reductase,

wherein the peptide is one of the following sequences:

(SEQ ID NO: 1)

Glu-Gly-Lys-Gly-Lys-Ser-Val-Val-Cys-Glu,

(SEQ ID NO: 2)

Glu-Gly-Lys-Gly-Lys-Ser-Val-Val,

(SEQ ID NO: 3)

Asp-Gly-Lys-Gly-Lys-Thr,

(SEQ ID NO: 4)

Arg-Gly-Lys-Ser,

(SEQ ID NO: 5)

Arg-Gly-Lys-Ser-NH 2 ,

(SEQ ID NO: 6)

Arg-Gly-Lys-Thr,

(SEQ ID NO: 7)

Arg-Gly-Lys-Thr-NH 2 ,

(SEQ ID NO: 8)

Lys-Gly-Lys-Ser,

(SEQ ID NO: 9)

Lys-Gly-Lys-Ser-NH 2,  and

(SEQ ID NO: 10)

Gly-Lys-Ser-NH 2 .

11. The method according to claim 10 , wherein the peptide is solubilized in one or more physiologically acceptable solvents selected from the group consisting of water, glycerol, ethanol, propanediol, propylene glycol, butylene glycol, dipropylene glycol, ethoxylated diethylene glycol or propoxylated diethylene glycol, cyclic polyols, white petroleum jelly, vegetable oil, and combinations thereof.

12. The method according to claim 10 , wherein the peptide is present at a concentration of between 0.0005 and 500 ppm.

13. The method according to claim 10 , wherein the peptide is present at a concentration of between 0.01 and 5 ppm.

14. The method of claim 10 , comprising strengthening the barrier function of the epidermis and stimulating epidermal differentiation by topically administering the composition.

15. The method of claim 10 , wherein the cosmetic treatment comprises treating against external stresses or cutaneous signs of aging and photo aging.

16. The method of claim 10 , wherein the cosmetic treatment comprises treating hypersensitive, irritated or reactive skin.

17. The method of claim 10 , wherein the cosmetic treatment comprises treating atopic eczema.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jan 10, 2020
From: THE BANK OF NOVA SCOTIA
To: AVOCA LLC; HERCULES LLC; ISP INVESTMENTS LLC; PHARMACHEM LABORATORIES LLC
Reel/Frame 051557/0504 →
SECURITY AGREEMENT Recorded Jul 3, 2017
From: AVOCA, INC.; HERCULES LLC; ISP INVESTMENTS LLC; PHARMACHEM LABORATORIES, INC.
To: THE BANK OF NOVA SCOTIA, AS ADMINISTRATIVE AGENT
Reel/Frame 043084/0753 →
CONVERSION Recorded Jan 30, 2017
From: ISP INVESTMENTS INC.
To: ISP INVESTMENTS LLC
Reel/Frame 041556/0499 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2011
From: DAL FARRA, CLAUDE; DOMLOGE, NOUHA; BOTTO, JEAN-MARIE
To: ISP INVESTMENTS INC.
Reel/Frame 026701/0769 →
Priority Claims (1)
FR 08 07364 · Dec 23, 2008 · national
Continuity (1)
Related Publication 20110286991A1 · Nov 24, 2011